Incannex Inks Manufacturing Agreement for Psilocybin Drug Product

Incannex Healthcare Limited (Nasdaq: IXHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has engaged a manufacturer for the development and production of its psilocybin drug product.

Catalent Australia will develop and manufacture a cGMP-grade psilocybin drug product for use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development program and potential wider commercial use.

Highlights

• Catalent has been engaged to develop the formulation, generate required quality and stability data for regulatory filings.
• The manufacturer will also establish cGMP manufacture of a drug product to be used in future clinical trials.
• The proposed manufacturing process will be designed to be scalable to commercial supply levels when appropriate.

Incannex described the partnership as an important milestone for its PsiGAD program. The company believes its therapy has the potential to help millions of people whose lives are seriously impacted by severe anxiety and for whom current treatment options have not been effective.

Incannex Healthcare has signed a manufacturing agreement for its psilocybin drug product.

The product will be used in Incannex’s psychotherapy drug development program and for potential wider commercial use